Inhibitor Therapeutics, Inc.
Datakwaliteit: 83%
INTI
OTC
Manufacturing
Chemicals
€ 0,10
▲
€ 0,02
(25,00%)
Marktkapitalisatie: 17,26 M
Prijs
€ 0,10
Marktkapitalisatie
17,26 M
Dagbereik
€ 0,08 — € 0,08
52-Weeksbereik
€ 0,03 — € 0,12
Volume
30.001
Openen € 0,08
50D / 200D Gem.
€ 0,08
20,63% above
50D / 200D Gem.
€ 0,06
72,41% above
Quick Summary
Belangrijkste Punten
Negative free cash flow of -3,23 M
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-917,92%
Onder sectorgemiddelde (-53,47%)
ROIC-79,44%
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current Ratio35,00
Interest CoverageN/A
Waardering
PE (TTM)
-5,23
Onder sectorgemiddelde (-1,47)
P/B Ratio4997,79
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -5,2 | -1,5 |
| P/B | 4997,8 | 1,6 |
| ROE % | -917,9 | -53,5 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -3,30 M |
| ROE | -917,92% | ROA | -93,72% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -3,23 M |
| ROIC | -79,44% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 35,00 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 2,98 M | Tangible Book Value | 3.453 |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -5,23 | Forward P/E | N/A |
| P/B Ratio | 4997,79 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -18,72% | ||
| Market Cap | 17,26 M | Enterprise Value | 14,28 M |
| Per Share | |||
| EPS (Diluted TTM) | -0,02 | Revenue / Share | N/A |
| FCF / Share | -0,02 | OCF / Share | -0,02 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 97,91% |
| SBC-Adj. FCF | -3,25 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | 0,0 |
| Net Income | -3,30 M | -3,34 M | -3,03 M | 12,11 M | -298.632,0 |
| EPS (Diluted) | -0,02 | -0,02 | -0,02 | 0,03 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -3,43 M | -3,66 M | -3,40 M | -657.926,0 | -325.395,0 |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 1,70 M | 1,68 M | 1,38 M | 6.150,0 | 4.905,0 |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | — | — | 23.234,0 | 23.234,0 | -14.837,0 |
| Income Tax | — | — | 55.109,0 | 55.109,0 | 0,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 2,51 M | 5,69 M | 8,95 M | 11,98 M | 58.784,0 |
| Total Liabilities | 3,80 M | 3,71 M | 3,67 M | 3,68 M | 3,68 M |
| Shareholders' Equity | -1,29 M | 1,99 M | 5,28 M | 8,30 M | -3,62 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 2,38 M | 5,61 M | 8,84 M | 11,95 M | 30.626,0 |
| Current Assets | 2,45 M | 5,69 M | 8,95 M | 11,98 M | 58.784,0 |
| Current Liabilities | 766.330,0 | 709.618,0 | 665.164,0 | 678.782,0 | 679.630,0 |
{"event":"ticker_viewed","properties":{"ticker":"INTI","listing_kind":"stock","pathname":"/stocks/inti","exchange":"OTC","country":"US"}}